The Deubiquitinase USP39 Promotes Esophageal Squamous Cell Carcinoma Malignancy as a Splicing Factor

Genes (Basel). 2022 May 3;13(5):819. doi: 10.3390/genes13050819.

Abstract

Esophageal squamous cell carcinoma (ESCC) is an aggressive epithelial malignancy and the underlying molecular mechanisms remain elusive. Here, we identify that the ubiquitin-specific protease 39 (USP39) drives cell growth and chemoresistance by functional screening in ESCC, and that high expression of USP39 correlates with shorter overall survival and progression-free survival. Mechanistically, we provide evidence for the role of USP39 in alternative splicing regulation. USP39 interacts with several spliceosome components. Integrated analysis of RNA-seq and RIP-seq reveals that USP39 regulates the alternative splicing events. Taken together, our results indicate that USP39 functions as an oncogenic splicing factor and acts as a potential therapeutic target for ESCC.

Keywords: ESCC; USP39; splicing factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Esophageal Neoplasms* / genetics
  • Esophageal Squamous Cell Carcinoma* / genetics
  • Humans
  • RNA Splicing Factors / genetics
  • Ubiquitin-Specific Proteases / genetics
  • Ubiquitin-Specific Proteases / metabolism

Substances

  • RNA Splicing Factors
  • USP39 protein, human
  • Ubiquitin-Specific Proteases

Grants and funding

This study was supported by the National Natural Science Foundation of China (82072756), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-067), the fund of the “San-ming” Project of Medicine in Shenzhen (SZSM201812062), and Guangdong Basic and Applied Basic Research Foundation (2019B030302012).